Relay Therapeutics

Today, we announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies, a group of rare disorders characterized by abnormal development of blood vessels, lymphatic vessels, and surrounding tissues. The data, being presented this week at #ISSVA2026, demonstrated symptomatic improvement at 12 weeks in nearly all patients while maintaining a safety and tolerability profile showing potential for chronic use. These findings also support the potential advantage of PI3Kα mutant-selective inhibition. Click below for additional insights and more from President of R&D Don Bergstrom. ir.relaytx.com/news-releases/…

Today, we reported first quarter 2026 financial results and highlighted continued progress across our pipeline. Details here. ir.relaytx.com/news-releases/…

Today, we're pleased to announce new clinical data and plans to move zovegalisib + atirmociclib triplet combination into Phase 3 development in frontline patients with PI3Kα-mutated, HR+/HER2- metastatic #breastcancer. We aim to initiate this study early next year. Join us this morning, April 27, at 8:30am ET for our conference call to learn more. ir.relaytx.com/news-releases/…

In continued recognition of International Children’s Book Day, Relay Tx acknowledges that children’s books can help communicate feelings and experiences related to rare diseases that are often hard to explain. For families living with vascular anomalies, everyday life can include navigating uncertainty, feelings of isolation, and comments about visible differences that can feel overwhelming, especially for children. By honestly explaining these unique journeys and experiences, children's books can help empower individuals and build understanding and acceptance. Today, we celebrate stories that shine a light on rare conditions and remind families that their experiences matter. They are not alone. Learn more about vascular anomalies children’s books and CLOVES Syndrome at lnkd.in/djrZQnh and FAVA at lnkd.in/eGvpDbji.

In the spirit of International Children’s Book Day last week, Relay Tx recognizes the power of children’s books to explain challenging topics in ways that are honest and compassionate. For families impacted by breast cancer, children's books can help open dialogue, normalize emotions, and remind families that they are not alone. These books can be a gentle way to support understanding, resilience, and connection during challenging moments. So today, we honor the authors, illustrators, patients, and families who use storytelling as a tool for comfort, courage, and care. Learn more about children’s books available for the breast cancer community: lbbc.org/about-breast-c…

New today: We’ve published a webinar focused on Vascular Anomalies education, intended to support broader understanding of the disease area, existing therapeutic options & ongoing clinical development of zovegalisib, our mutant-selective PI3Kα inhibitor. relaytx.com/pipeline

More: ir.relaytx.com/news-releases/…

We're pleased to share Ph1/2 data from the ReDiscover trial at the 400mg BID fed dose of zovegalisib+fulvestrant in patients w/ PI3Kα-mutated, HR+/HER2- metastatic #breastcancer at ESMO TAT, supporting our decision to advance this regimen into the ongoing Ph3 ReDiscover-2 trial.

We were on the ground at #MBCC26 & were grateful for the opportunity to connect with investigators, research partners, & the #breastcancer community as we continue advancing innovative therapies for patients. Thanks to all who joined for our ReDiscover and ReDiscover-2 posters.

We were pleased to host BOD member Linda Hill & her coauthor Emily Tedards, as part of a tour for their new book “Genius at Scale.” They shared insights on building innovative companies by creating trust, encouraging bold ideas & fostering collaboration. Thank you Linda & Emily!

Today, we are pleased to report fourth quarter and full year 2025 financial results along with anticipated 2026 milestones. Listen below as CEO @SanjivKPatel1 shares more about the year ahead. Full details here. ir.relaytx.com/news-releases/…

Ahead of #RareDiseaseDay, we gathered to better understand rare diseases & experiences of those living with them. As we advance our research in vascular anomalies & Fabry disease, we are today reminded of the unmet need in rare diseases & reinforce our commitment to patients.

Relay Tx was excited to join the kickoff session for the @CLOVESSyndrome International CLOVES Summit. As the event sponsor, we're grateful to participate in an event that will bring together patients, families, and researchers. Learn more about the summit: clovessyndrome.org/current-event/…

We will present initial Phase 1/2 data of zovegalisib plus fulvestrant at the 400mg BID fed dose (the Phase 3 dose) in CDK4/6-experienced patients this March at #ESMOTAT26. Details here: ir.relaytx.com/news-releases/…

Today, we announced that the US FDA has granted zovegalisib Breakthrough Therapy Designation for PIK3CA-mutant, HR+/HER2- advanced #breastcancer, supported by data from our ReDiscover trial testing zovegalisib at the 600mg BID fasted & 400mg BID fed doses in combo w/ fulvestrant.

Santa only puts in one long shift. Relayers put in a full year of dedication. 2025 was a busy one and now it’s time to slow down, recharge, and celebrate with family, friends, and our little pastry chefs!

Today at #SABCS25, we are pleased to announce an efficacy subset analysis of zovegalisib (RLY-2608) + fulvestrant from the Phase 1/2 ReDiscover trial in PI3Kα-mutated, metastatic #breastcancer patients. Learn more here. ir.relaytx.com/news-releases/…

Join us at #SABCS25 this week! We look forward to sharing the latest updates from our ongoing #breastcancer clinical trials this Friday. More details below.

Before Relayers brave the Thanksgiving traffic 🚗 Before we soak the turkey in a brine 🦃 Employees soaked in the spirit of gratitude, writing handwritten thank notes to colleagues across the organization 📨 Who doesn't like getting mail!? 📬 Happy Thanksgiving!

Congratulations to @EuropaDonna’s 17th Pan European Conference for once again bringing leaders and patients together from across Europe to advocate for advances in breast cancer care.